Levosimendan: A New Therapeutical Strategy in Patients with Renal Insufficiency
Cardiovascular Drugs and Therapy · 2025
DOI: 10.1007/s10557-024-07614-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Drugs and Therapy, 2025. Verfasst von Xinwen Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, the Affiliated Hospital of Shaoxing University, Shaoxing, 312000, PR China. Hauptthemen laut MEDLINE: Renal Insufficiency, Cardiotonic Agents, Pyridazines, Hydrazones. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Zhejiang Medical and Health Science and Technology, Science and Technology Projects in the Zhejiang Province Department of Education.
Abstract (Originalsprache)
Levosimendan, a Ca2 + sensitizer with positive inotropic effects, is primarily employed for the short-term treatment of acute decompensated heart failure (ADHF). Levosimendan exerts renal function protection through various mechanisms, including anti-apoptosis, anti-inflammatory, and antioxidant effects in vivo. Additionally, levosimendan may have a protective effect on individuals with heart failure and renal insufficiency, as well as on renal function impairment after cardiac surgery. However, the application of levosimendan in patients with severe renal dysfunction remains controversial. This article delves into the use of levosimendan in severe renal insufficiency, explores its impact on renal function, and provides a comprehensive overview of its impact on renal function after cardiac surgery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, the Affiliated Hospital of Shaoxing University, Shaoxing, 312000, PR China.
- Department of Cardiovascular Medicine, the Affiliated Hospital of Shaoxing University, Shaoxing, 312000, PR China.
- Clinical Pharmacy Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China.
- Department of Cardiovascular Medicine, the Affiliated Hospital of Shaoxing University, Shaoxing, 312000, PR China. fuyongping@usx.edu.cn.
- Clinical Pharmacy Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China. huying@hmc.edu.cn.
ORCID-Profile: Yongping Fu, Ying Hu
Förderung
- National Natural Science Foundation of China
- Zhejiang Medical and Health Science and Technology
- Science and Technology Projects in the Zhejiang Province Department of Education
- Shaoxing Health Science and Technology Plan Project
- Zhejiang Medical Association Clinical Medicine Project
- the Ministry of Education Industry-University Cooperative Education Project
Zitieren
APA
Liu, X., Lu, M., Yu, Y., Shen, N., Xia, H., Shi, J., Fu, Y., & Hu, Y. (2025). Levosimendan: A New Therapeutical Strategy in Patients with Renal Insufficiency. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-024-07614-9
Vancouver
Liu X, Lu M, Yu Y, Shen N, Xia H, Shi J, et al. Levosimendan: A New Therapeutical Strategy in Patients with Renal Insufficiency. Cardiovascular Drugs and Therapy. 2025. doi:10.1007/s10557-024-07614-9
BibTeX
@article{Liu2025,
author = {Liu, Xinwen and Lu, Mengkai and Yu, Yanna and Shen, Nannan and Xia, Haijiang and Shi, Jiana and Fu, Yongping and Hu, Ying},
title = {Levosimendan: A New Therapeutical Strategy in Patients with Renal Insufficiency},
journal = {Cardiovascular Drugs and Therapy},
year = {2025},
doi = {10.1007/s10557-024-07614-9}
}
EUVIMED